
Milam15 mg
Eskayef Bangladesh Ltd.
Midazolam is a short-acting benzodiazepine used mainly in hospital and clinical settings, under the supervision of trained healthcare professionals.
Midazolam is a short-acting benzodiazepine used mainly in hospital and clinical settings, under the supervision of trained healthcare professionals.
All uses of Midazolam require administration or prescribing by a qualified healthcare professional; it is not intended for unsupervised self-medication.
Dosing of Midazolam must always be individualized by a healthcare professional according to indication, age, body weight, renal/hepatic function, and concomitant medications. Doses below are general references and do not replace clinical judgment.
| Indication | Typical adult dose | Notes |
|---|---|---|
| Procedural sedation (IV) | Initial 1-2.5 mg slow IV over at least 2 minutes; titrate to effect | Reduce dose in elderly/debilitated patients and when opioids are co-administered |
| Preoperative sedation (IM) | Approximately 0.07-0.1 mg/kg, 30-60 minutes before surgery | Administered by trained personnel |
| Induction of anesthesia (IV) | Individualized; per anesthesiologist's protocol | Given only by anesthesia providers |
| Continuous ICU sedation (IV infusion) | Individualized infusion rate, titrated to sedation goal | Requires continuous monitoring |
| Status epilepticus / acute seizures | Per emergency protocol (IM, buccal, or intranasal) | Given as first-line therapy when IV access is unavailable |
| Short-term insomnia (oral, where approved) | 7.5-15 mg at bedtime; elderly 7.5 mg | Limit to a few days; not for routine long-term use |
Weight-based and route-specific; generally higher mg/kg doses are needed in younger children. Always calculated and administered by a clinician experienced in pediatric sedation.
Dose reduction and closer monitoring are required in hepatic or renal impairment, as both prolong the sedative and respiratory-depressant effects of Midazolam (see Use in Special Populations).
Adverse effects of Midazolam vary by route and dose. The most serious risk, respiratory depression and apnea (see Precautions and Warnings), is more common with intravenous administration, higher doses, or concomitant CNS depressants.
Midazolam is contraindicated in:
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.